1Burke WJ, Gergel I,Bose A. Fixed-dose trial of the singleisomer SSRI escitalopram in depressed outpatients [ J]. ClinPsychiatry,2002, 8 (4) : 331 -336.
2Wade A, Michael Lemming 0,Bang Hedegard K. Escitalo-pram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care [ J] . lnt Clin-Psychopharmacol, 2002, 17: 95 -102.
3Lepola U, Loft H, Reines EH. Escitalopram ( 10-20mg/d)is effective and well tolerated in a placebo-controlled study indepression in primary care [ J ]. International clinicalpsychopharmacology, 2003 , 18:211 -217.
4Davidson J,Bose A,Su G. Escitalopram in the treatment ofgeneralized anxiety disorder : double blinded, placebocontrolled flexible-dose study [ J]. Depression and Anxiety,2004, 19:234 -240.
5Kasper S,Loft H, Smith JR. Escitalopram in the treatmentof social anxiety disorder; randomized, placebo-controlled,flexible-dosage study [ J ]. British journal of psychiatry,2005,18: 222 -226.
6Stahl S, Gergel I,Li D. Escitalopram in the treatment ofpanic disorder : a randomized, double-blind, placebo-controlled trial [ J]. J Clin Pschiatry,2003,64(11 ) : 1322-1327.
7Kennedy SH,Andersen HF,Lam RW. Efficacy of escitalopram inthe treatment of major depressive disorder compared withconventional selective serotonin reuptake inhibitors andvenlafaxine XR : a meta-analysis [ J ]. PsychiatryNeuroscience,2006,3 1(2) : 122 ~ 131.
8Murdoch D, Keam SJ. A review of its use in the management ofmajor depressive disorder[ J]. Drugs,2005 ,65 (16) :2378 -2383.
9John Waugh, Karen L. A review of its use in the managementof major depressive and anxiety disorders [ J ]. CNS drugs2003, 17(5) :343 -362.
10Borwin Bandelow, Henning F,Andersen, et al. Escitalopram inthe treatment of anxiety symptoms associated withdepression [ J]. Depression and anxiety, 2007, 24: 53 -61.
4Jesse S, Kassubek J, Muller HP, et al. Signal alterations of the basal ganglia in the differential diagnosis of Parkinson's disease : a retrospective case - controlled MRI data bank analysis [ J ]. BMC Neurol, 2012,12 : 163.
5Gerlach M, Halley P, Riederer P, et al. The effect of piribedil on L- DOPA -induced dyskinesias in a rat model of Parkinson's disease: differ- ential role of or(2) adrenergic mechanisms[J] . J Neural Transm, 2013, 120(1):31 -36.
10Jesse S, Kassubek J, Muller HP, et al. Signal alternations of the basal ganglia in the differential diagnosis of Parkinson's disease : a retrospec- tive case-controlled MRI data bank analysis[ J]. BMC Neurol, 2012, 12 : 163.
